BETA

Activities of Marco AFFRONTE related to 2017/2951(RSP)

Plenary speeches (1)

Vaccine hesitancy and drop in vaccination rates in Europe (debate) IT
2016/11/22
Dossiers: 2017/2951(RSP)

Institutional motions (1)

MOTION FOR A RESOLUTION on vaccine hesitancy and the drop in vaccination rates in Europe PDF (280 KB) DOC (61 KB)
2016/11/22
Dossiers: 2017/2951(RSP)
Documents: PDF(280 KB) DOC(61 KB)

Oral questions (2)

Vaccine hesitancy and the drop in vaccination rates in Europe PDF (187 KB) DOC (18 KB)
2016/11/22
Dossiers: 2017/2951(RSP)
Documents: PDF(187 KB) DOC(18 KB)
Vaccine hesitancy and the drop in vaccination rates in Europe PDF (185 KB) DOC (18 KB)
2016/11/22
Dossiers: 2017/2951(RSP)
Documents: PDF(185 KB) DOC(18 KB)

Amendments (7)

Amendment 12 #

Paragraph 1 a (new)
1 a. Recognises the potential role vaccines can play in reducing the need for antibiotics, thereby helping to limit the spread of Anti-Microbial Resistance (AMR), which should continue to be explored; stresses however that urgently reducing the overuse and misuse of, and unintended exposure to, antibiotics must remain a top priority.
2018/01/31
Committee: ENVI
Amendment 28 #

Paragraph 4 a (new)
4 a. Calls on the Commission to elaborate guidelines defining conditions (coverage percentage, epidemic phenomena, etc.) and criteria that can conduct to a compulsory vaccination mechanism, in order to have harmonized guidelines for all Member States.
2018/01/31
Committee: ENVI
Amendment 31 #

Paragraph 4 b (new)
4 b. Calls on the Member States and the Commission to reinforce legislative basis for immunization coverage. According to the objective 1 of the European Vaccine Action Plan 2015– 2020, introducing and implementing an appropriate legislative framework is crucial to define national priorities and to concretize a sustainable commitment to immunization.
2018/01/31
Committee: ENVI
Amendment 32 #

Paragraph 4 c (new)
4 c. Stresses the importance to create an innovative financing mechanism to allocate funding for immunisation at affordable prices and high-quality supply, identifying any funding gaps thorough MS, in line with the goal 6 and the objective 5 of the European Vaccine Action Plan 2015–2020, in order to achieve financial sustainability of national immunization programmes.
2018/01/31
Committee: ENVI
Amendment 38 #

Paragraph 7 a (new)
7 a. Whereas in order to ensure the highest protection of human health and to reduce vaccine hesitancy, the chances of any negative health effects resulting from, or perceived to result from vaccinations, however rare, need to be reduced as much as possible; Calls on Member States to consider the introduction of a preventive and precautionary pre-vaccination test, at least for some fragile and vulnerable categories of patients, which takes into consideration, inter alia, their age, intolerances and health condition, in order to help prevent any adverse health reactions and to therefore also counter vaccine hesitancy.
2018/01/31
Committee: ENVI
Amendment 85 #

Paragraph 18
18. Calls on the Commission and the Member States to elaborate a fully comprehensive EU Action Plan raising the social problem of vaccine hesitancy, strengthening Member States’ commitments, including priority and region-specific actions, and taking into account the varying circumstances and specific challenges faced by the Member States;in line with the European Vaccine Action plan 2015- 2020.
2018/01/31
Committee: ENVI
Amendment 98 #

Paragraph 20
20. Calls on the Member States to punctually provide data on vaccination; Moreover, member States have to monitor and report every year to the regional offices all progresses made, remaining challenges and updated actions to reach the national immunizations targets.
2018/01/31
Committee: ENVI